

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 8, 2021

Andrew McBride Chief Financial Officer Gores Metropoulos II, Inc. 6260 Lookout Road Boulder, CO 80301

> Re: Gores Metropoulos II, Inc. Amendment No. 5 to Registration Statement on Form S-4 Filed November 26, 2021 File No. 333-257726

Dear Mr. McBride:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our November 18, 2021 letter.

Amendment No. 5 to Registration Statement on Form S-4 Filed November 26, 2021

General

- 1. We note your revisions in response to comment 1 and reissue the comment in part. Please revise your Summary and where appropriate to compare the per share price of the New PIPE Investment with the estimated price at which Public Stockholders may redeem shares of your Class A Stock, further quantifying the effective percentage discount between such prices.
- 2. We note your response to comment 4. Please revise the cover page and where appropriate to explain how Rollover Options may result in an additional 11,383,245 shares being issued, further adding to dilution.

Andrew McBride Gores Metropoulos II, Inc. December 8, 2021 Page 2

3. Please revise the Cover Page and Summary to explain the rollover options in plain English. For example, who receives them? Why do they not "receive their portion" of the approximately 190 million post combination company's common stock? Please revise accordingly.

Summary

<u>Interests of Certain Persons in the Business Combination</u> <u>Interests of the Company Initial Stockholders..., page 64</u>

4. We note your revisions in response to comment 5 that the Sponsor will pay "a weighted average per share price of \$9.60 for each share of Common Stock" to be purchased in the PIPE Investments. Please revise to disclose the weighted average per share price that your Sponsor will have paid for its total Common Stock in the Post-Combination Company, both in the event that your Sponsor does and does not exercise its rights to assign any of its PIPE Shares. In this regard, advise us whether the Sponsor will have paid a weighted average per share price of approximately \$4.24 for each share of Common Stock if it does not assign any of its PIPE Shares, and only a nominal amount if it assign all of its PIPE Shares. Please make corresponding revisions when discussing the Share Surrender Agreement, including on the cover page and page 50, and the Additional Sponsor Commitment, including on page 52.

The Business Combination

Recommendation of Our Board of Directors..., page 184

5. We note your response to comment 7. Please revise, as indicated in your response, to disclose the apparent belief of the Board of Directors that the growth projections and underlying assumptions continued to be reasonable despite the decline in enterprise valuation.

<u>Certain Financial Projections Provided to Our Board</u> <u>Material Assumptions Underlying the Financial Projections, page 205</u>

6. We note your revisions in response to comment 9. Please revise to provide more detailed disclosure of your growth assumptions for RevPAR, Ending Live Units & Contracted Units, and Bookable Nights, as well as the reasons you believe these assumptions are reasonable. For example, we note your revised disclosure that in 2019 Sonder expanded into markets which typically earn lower RevPAR as compared to the existing markets. This appears consistent with the observation that Sonder's actual Revenue per Available Room decreased during a period of rapid growth, but it is unclear what assumptions support the projection that RevPAR will exceed Sonder's pre-COVID-19 performance in the near future. Please revise accordingly.

Andrew McBride Gores Metropoulos II, Inc. December 8, 2021 Page 3

The Merger Agreement and Related Agreements
The Merger Agreement
Delayed Draw Note Term Sheet, page 256

- 7. We note your revisions in response to comment 2. Please revise the Cover Page, Summary, Risk Factors, Management's Discussion and Analysis and where appropriate to address the possibility that you do not obtain financing under the non-binding Delayed Draw Notes. Will the transaction move forward if the financing is not obtained? Do you anticipate investors receiving updated disclosure in the event the financing is not obtained or materially changed, and if so what is the timing and nature of the intended disclosure? With respect to the terms of the notes, please provide further clarification. For example, please disclose:
 - the 1% LIBOR floor for your interest rate, as well as the LIBOR replacement rate,
 - the material restrictions on the incurrence of additional debt and the cap on existing debt, and
 - the GAAP net revenue conditions applicable to any second draw or disclose that an Initial Draw will not occur on or prior to December 31, 2021.

You may contact William Demarest at (202) 551-3432 or Robert Telewicz at (202) 551-3438 if you have questions regarding comments on the financial statements and related matters. Please contact Christopher Dunham at (202) 551-3783 or James Lopez at (202) 551-3536 with any other questions.

Sincerely,

Division of Corporation Finance Office of Real Estate & Construction

cc: James R. Griffin, Esq.